2013
DOI: 10.1371/journal.pone.0062733
|View full text |Cite
|
Sign up to set email alerts
|

Healthy Volunteers Can Be Phenotyped Using Cutaneous Sensitization Pain Models

Abstract: BackgroundHuman experimental pain models leading to development of secondary hyperalgesia are used to estimate efficacy of analgesics and antihyperalgesics. The ability to develop an area of secondary hyperalgesia varies substantially between subjects, but little is known about the agreement following repeated measurements. The aim of this study was to determine if the areas of secondary hyperalgesia were consistently robust to be useful for phenotyping subjects, based on their pattern of sensitization by the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
52
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 32 publications
(56 citation statements)
references
References 23 publications
4
52
0
Order By: Relevance
“…Any effect of peri-operative melatonin would vary with dosage, administration route and timing. A robust doseresponse relationship for melatonin has yet to be demonstrated in humans, which might be provided in non-clinical settings [38,39].…”
Section: Discussionmentioning
confidence: 99%
“…Any effect of peri-operative melatonin would vary with dosage, administration route and timing. A robust doseresponse relationship for melatonin has yet to be demonstrated in humans, which might be provided in non-clinical settings [38,39].…”
Section: Discussionmentioning
confidence: 99%
“…It has been used extensively for pharmacodynamic research (Brennum et al, 2001, Werner et al, 2001, Dirks et al, 2002a, Dirks et al, 2002b, Werner et al, 2002a, Werner et al, 2002b, Dirks et al, 2003, Ravn et al, 2012, Ravn et al, 2013). Sensitization is transient, reversible and replicable (Werner et al, 2013). We recently reported that low dose naloxone (0.021 mg/kg, i.v.…”
Section: Conceptual Model Conclusion and Clinical Significancementioning
confidence: 99%
“…For example, studies using microdialysis to evaluate pharmacokinetics of dermal drug application reported between-subject variability to be the primary source of variability in the assay, complicating the measurement of drug bioequivalence (25,26). Human experimental pain models using capsaicin or heat to evoke secondary hyperalgesia also find that between-subject heterogeneity is a major source of variability (27). Inherent individual differences in pain neurotransmission create a challenge in the design of clinical/translational pain studies using human subjects or tissues.…”
Section: Discussionmentioning
confidence: 99%